

Justification Document for the Selection of a CoRAP Substance

Substance Name (public name):	N-methylaniline
EC Number:	202-870-9
CAS Number:	100-61-8
Authority:	Bureau for Chemical Substances, Poland

Date:

Cover Note

19/03/2019

This document has been prepared by the evaluating Member State given in the CoRAP update.

Table of Contents

1	IDENTITY OF THE SUBSTANCE	3
1.1	Other identifiers of the substance	3
1.2	Similar substances/grouping possibilities	3
2	OVERVIEW OF OTHER PROCESSES / EU LEGISLATION	5
3	HAZARD INFORMATION (INCLUDING CLASSIFICATION)	6
3.	Classification 1.1 Harmonised Classification in Annex VI of the CLP 1.2 Self classification	6 6
4	INFORMATION ON (AGGREGATED) TONNAGE AND USES	7
4.1	Tonnage and registration status	7
4.2	Overview of uses	7
_	JUSTIFICATION FOR THE SELECTION OF THE CANDIDAT RAP SUBSTANCE	E 8
5.1.	Legal basis for the proposal	8
5.2. CoR		8
5.3. Eva	Initial grounds for concern to be clarified under Substance luation	8
5.4.	······································	10
leq		

1 IDENTITY OF THE SUBSTANCE


1.1 Other identifiers of the substance

N-methylaniline EC name (public): Benzenamine, N-methyl-N-Methvaniline IUPAC name (public): N-methyl-N-phenylamine N-methylaniline Index number in Annex VI of the CLP 612-015-00-5 **Regulation:** Molecular formula: C7H9N Molecular weight or molecular weight 107.15 range: (Methylamino)benzene Benzenamine, N-methylmethylaniline-n Synonyms: Methylphenylamine MONOMETHYLANILINE

Table: Other Substance identifiers

Type of substanceImage: Mono-constituentImage: Multi-constituentImage: UVCB


Structural formula:



1.2 Similar substances/grouping possibilities


• N,N-dimethylaniline

EC: 204-493-5 CAS: 121-69-7 Mol. formula: C8H11N



• Aniline

EC no.: 200-539-3 CAS no.: 62-53-3 Mol. formula: C6H7N



2 OVERVIEW OF OTHER PROCESSES / EU LEGISLATION

Table: Completed or ongoing processes

RMOA	🗌 Risk Manag	ement Option Analysis (RMOA)	
		Compliance check	
	Evaluation	🛛 Testing proposal	
REACH		□ CoRAP and Substance Evaluation	
Processes	Authorisation	Candidate List	
	Authorisation	Annex XIV	
	Restriction	□ Annex XVII ¹	
CLH	🗆 Annex VI ((CLP) (see section 3.1)	
	\Box Plant Protection Products Regulation		
Processes under other	Regulation (EC) No 1107/2009		
EU legislation	Biocidal Product Regulation		
	Regulation (EU) 528/2012 and amendments		
Previous	□ Dangerous substances Directive 67/548/EEC (NONS)		
legislation	\Box Existing Substances Regulation 793/93/EEC (RAR/RRS)		
(UNEP) Stockholm		t	
convention (POPs Protocol)	□ In relevant Annex		
Other processes/ EU legislation	\Box Other (provide further details below)		
Further			

¹ Please specify the relevant entry.

3 HAZARD INFORMATION (INCLUDING CLASSIFICATION)

3.1 Classification

3.1.1 Harmonised Classification in Annex VI of the CLP

Index number: 612-015-00-5

- Acute Tox. 3 *, H301
- Acute Tox. 3 *, H311
- Acute Tox. 3 *, H331
- STOT RE 2 *, H373
- Aquatic Acute 1, H400
- Aquatic Chronic 1, H410

3.1.2 Self classification

The following hazard classes are in addition notified among the aggregated self classifications in the C&L Inventory:

- Acute Tox. 3, H301
- Acute Tox. 3, H311
- Acute Tox. 3, H331
- Skin Irrit. 2, H316
- Eye Irrit. 2, H319, H320
- Muta. 2, H341
- Carc. 2, H351
- STOT RE 2, H373 (affected organs: target: spleen, liver and bone marrow; route of exposure: oral and Inhalation)
- Aquatic Acute 1, H400
- Aquatic Chronic 1, H410

4 INFORMATION ON (AGGREGATED) TONNAGE AND USES²

4.1 Tonnage and registration status

Table: Tonnage and registration status

From ECHA dissemination site *				
☑ Full registration(s) (Art. 10)		\Box Intermediate registration(s) (Art. 17 and/or 18)		
Tonnage band (as per disseminat	ion s	ite)		
🗆 1 – 10 tpa		10 – 100 tpa	🖾 100 – 1000 tpa	
🗆 1000 – 10,000 tpa		10,000 – 100,000 tpa	🗆 100,000 – 1,000,000 tpa	
□ 1,000,000 – 10,000,000 tpa □ 10,000,000 – 100,000,000 tpa			□ > 100,000,000 tpa	
□ <1 >+ tpa (e.g. 10+ ; 100+ ; 10,000+ tpa) □ Confidential				
This substance has 7 active registrations under REACH, 2 Joint Submission(s) and 2 Individual Submission(s).				

*the total tonnage band has been calculated by excluding the intermediate uses, for details see the Manual for Dissemination and Confidentiality under REACH Regulation (section 2.6.11): https://echa.europa.eu/documents/10162/22308542/manual dissemination en.pdf/7e0b87c2-2681-4380-8389-cd655569d9f0

4.2 Overview of uses

This substance is used by consumers, by professional workers (widespread uses), in formulation or re-packing, at industrial sites and in manufacturing.

Table: Uses

Part 1:

\boxtimes	\boxtimes	\boxtimes	\boxtimes	\boxtimes	Article	🛛 Closed
Manufacture	Formulation	Industrial	Professional	Consumer	service life	system
		use	use	use		
Dart 7:						

Part 2:			
	Use(s)		
Uses as	Manufacture of bulk, large scale chemicals (including petroleum		
intermediate	products in an industrial process)		
Formulation	Formulation of mixtures (including the application as additive in fuel)		
Uses at	Additive in fuels.		
industrial sites	Manufacturing of another substance (use of intermediates).		
Uses by	Cooling liquids in refrigerators, oil-based electric heaters, hydraulic		
professional	liquids in automotive suspension, lubricants in motor oil and break		
workers	fluids, fuels.		
Consumer Uses	Fuels, cooling liquids in refrigerators, oil-based electric heaters, hydraulic liquids in automotive suspension, lubricants in motor oil and break fluids.		
Article service			
life			

² The dissemination site was accessed August 2018.

5. JUSTIFICATION FOR THE SELECTION OF THE CANDIDATE CORAP SUBSTANCE

5.1. Legal basis for the proposal

 \Box Article 44(2) (refined prioritisation criteria for substance evaluation)

 \boxtimes Article 45(5) (Member State priority)

5.2. Selection criteria met (why the substance qualifies for being in CoRAP)

- \boxtimes Fulfils criteria as CMR/ Suspected CMR
- \Box Fulfils criteria as Sensitiser/ Suspected sensitiser
- $\hfill \square$ Fulfils criteria as potential endocrine disrupter
- □ Fulfils criteria as PBT/vPvB / Suspected PBT/vPvB
- \Box Fulfils criteria high (aggregated) tonnage (*tpa* > 1000)
- \boxtimes Fulfils exposure criteria
- \boxtimes Fulfils MS's (national) priorities

5.3. Initial grounds for concern to be clarified under Substance Evaluation

Hazard based concerns					
CMR C C M R	Suspected CMR ¹ \square C \square M \square R	Potential endocrine disruptor			
Sensitiser	□ Suspected Sensitiser ³				
PBT/vPvB	□ Suspected PBT/vPvB ¹	Other (please specify below)			
Exposure/risk based concer	'ns				
☑ Wide dispersive use	Consumer use	Exposure of sensitive populations			
Exposure of environment	Exposure of workers	☐ Cumulative exposure			
⊠ High RCR	High (aggregated) tonnage	□ Other (please specify below)			
<u>Mutagenicity</u>	Mutagenicity				
Data from the registration dossier:					
All studies on in-vitro gene mutation in bacteria with N-Methylaniline show negative results. A comet assay and a chromosomal aberration test with mammalian cells are also available, but these assays give a negative and positive result, respectively. However, the publication of the comet assay refers to earlier publications, which indicate N-methylaniline as mutagenic and carcinogenic. In addition, aniline and N, N-					

dimethylaniline, present as impurities above 1%, are both classified as carcinogenic (Carc. 2). Hence, N-methylaniline is considered to be potentially genotoxic.

Various Ames tests on multiple strains show that N-Methylaniline does not induce genetic toxicity in bacterial in-vitro tests. However two different mammalian in-vitro tests show contra-dictionary results. The doubts described above need to be clarified. According to the CLP regulation 1272/2008, classification of N-methylaniline (pure) does not include mutagenicity. However, N-methylaniline is suspected as being genotoxic based on the reported positive result in a chromosomal aberration test with mamalian cells.

Other available data:

A mutagenic effect was observed in an Ames test with Salmonella typhimurium strain TA98 and, to a lesser extent, with TA100 in the presence of metabolic activation (Recommendation from the Scientific Committee on Occupational Exposure Limits for N-Methylaniline, SCOEL/SUM/178, 2012).

N-Methylaniline induced chromosomal aberrations in cultured Chinese hamster lung (CHL/IU) cells after 6 hours of exposure with metabolic activation or 24 hours of exposure without metabolic activation. Aniline did not induce chromosomal aberrations in a different strain of Chinese hamster lung (Don) cells. In other studies, aniline showed positive genotoxic responses such as increasing the frequency of sister chromatid exchanges in human and hamster cells, increasing DNA damage in cultured mouse lymphoma cells, and transforming mouse Balb/3T3 cells. In in vivo studies, aniline increased the frequencies of micronucleus formation in bone marrow of rats and mice, and sister chromatid exchanges in bone marrow of mice, but not rats (Provisional Peer Reviewed Toxicity Values for N-Methylaniline, EPA/690/R-05/017F Final 8-03-2005).

Carcinogenicity

Data from the registration dossier:

According to the CLP regulation 1272/2008, classification of N-methylaniline (pure) does not include carcinogeicity. However, according to the same regulation, the test substance presented in this dossier should be classified as potential carcinogen based on its impurities (as stated on the ECHA dissemination site). In addition, this classification is further justified by the high similarity between N-methylaniline and these two impurities, aniline and N,N-dimethylaniline, together with the reported positive result in a chromosomal aberration test with mamalian cells.

Aniline and N,N-dimethylaniline, although negative in Salmonella tests, were clastogenic in cultured mammalian cells (Abdo, 1989). The clastogenic response with N,Ndimethylaniline increases in the presence of S9 and is observed at lower doses than with aniline. These observations are consistent with the hypothesis that a DNA-reactive arene oxide intermediate may be involved in the clastogenic activity of N,N-dimethylaniline. Further evaluation of existing data is needed.

Exposure of workers

³ <u>CMR/Sensitiser</u>: known carcinogenic and/or mutagenic and/or reprotoxic properties/known sensitising properties (according to CLP harmonized or registrant self-classification or CLP Inventory) <u>Suspected CMR/Suspected sensitiser</u>: suspected carcinogenic and/or mutagenic and/or reprotoxic

properties/suspected sensitising properties (not classified according to CLP harmonized or registrant selfclassification)

Suspected PBT: Potentially Persistent, Bioaccumulative and Toxic

The combinations of exposure scenarios results in cumulative exposure of humans consist of the exposure as worker via inhalation and dermalexposure routes, exposure via the environment and exposure as a consumer. The values for the summed RCR including contribution of exposure via the environment are often above 1, indicating a significant risk. It is clear that the exposure of workers at the industrial sites is the main contributing factor.

Potential concerns for mutagenicity and carcinogenicity exist in all workplace scenarios, as the main impurities are identified as a non-threshold carcinogens.

Additional information

Two testing proposal on vertebrate animals were submitted by registrant:

- Repeated dose toxicity by dermal route (Sub-chronic toxicity (90 day): dermal, OECD 408) and

- Toxicity to reproduction (extended one-generation reproductive toxicity study OECD 443).

ECHA has held a third-party consultation (lasted on 23/04/2018-23/04/2018), to call for available information on above testing proposals.

5.4. Preliminary indication of information that may need to be requested to clarify the concern

☐ Information on toxicological properties	Information on physico-chemical properties	
\Box Information on fate and behaviour	imes Information on exposure	
□ Information on ecotoxicological properties	 Information on uses Other (provide further details below) 	
Information ED potential		
<i>Please provide further details/explanation. The information here should be consistent with concerns given in 5.3.</i>		

5.5. Potential follow-up and link to risk management

	Harmonised C&L Restriction	□ Restriction		\boxtimes Other (provide further details)	
Depends on the substance evaluation results.					